Use of REGEN-COV in children after heart transplantation for treatment and post-exposure prophylaxis of COVID-19.
Dipankar GuptaStephanie A CliffordFrederick J FrickerPublished in: Cardiology in the young (2022)
COVID-19 pandemic continues to evolve and new variants like Delta and Omicron have been discovered. REGEN-COV is a recombinant human monoclonal antibody to the spike protein of SARS-CoV-2 which received emergency use authorisation for treatment and post-exposure prophylaxis in patients with high risk of progression to severe disease. We review our experience with use of REGEN-COV in paediatric heart transplant patients.
Keyphrases
- sars cov
- respiratory syndrome coronavirus
- monoclonal antibody
- end stage renal disease
- emergency department
- coronavirus disease
- recombinant human
- public health
- heart failure
- newly diagnosed
- young adults
- healthcare
- ejection fraction
- chronic kidney disease
- peritoneal dialysis
- early onset
- genome wide
- small molecule
- drug induced
- smoking cessation